Kommt bei Hana Bioscience ein möglicher Rebound?

Habe was interessantes gefunden. Mal schauen was die nächsten Tage so bringen.
Da ist doch viel Platz für Spekulationen.



Hana Biosciences to Report Third Quarter 2008 Results and Business Update On November 13, 2008
Thursday November 6, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, will announce its third quarter 2008 results on Thursday, November 13, 2008, after the close of the financial markets. Following the announcement, Hana Biosciences' management team will host a conference call to include a discussion of results and highlights of the third quarter 2008 and a business update at 5:00pm ET, 2:00pm PT.

in die richtige Richtung.
Schlusskurs in Amiland 0,24$ (+4,35%).

Am Donnerstag kommt der Quartalsbericht + Update.  
Hoffe auf gute Nachrichten.
Gestern gab es ein kleines Plus von 4,17%, Kurs 0,25$.

0,26 (+4%).
Morgen dann noch gute Nachrichten und die kleine Party kann beginnen.

Press Release Source: Hana Biosciences, Inc.


Hana Biosciences Reports Third Quarter 2008 Results
Thursday November 13, 4:00 pm ET


SOUTH SAN FRANCISCO, Calif., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced its financial results and operational highlights for the third quarter ended September 30, 2008.
``During the third quarter of 2008, we continued to achieve significant progress on advancing our pipeline of dose-intensifying and compliance-enhancing oncology product candidates that address sizeable commercial opportunities, as evidenced by the positive results from our two key pipeline candidates, Marqibo and menadione,'' said Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. ``We expect to build on this progress during the coming months as we continue to focus our investment spending, and we remain on track to achieve multiple near-term milestones, in these highest priority initiatives.''

Third Quarter 2008 Key Achievements



* Marqibo(r) for adult acute lymphoblastic leukemia (ALL): Hana's
  registration-enabling Phase 2 rALLy pivotal clinical trial of
  Marqibo (vincristine sulfate injection, OPTISOME(tm)) successfully
  achieved the pre-specified protocol requirement of at least 3
  complete responses or complete responses without full platelet
  recovery among the first 29 evaluable patients to proceed to full
  enrollment of 56 patients with ALL in second relapse.  After Hana
  completes enrollment of the first 29 patients, the data will be
  submitted to the Independent Data Monitoring Committee (IDMC),
  which will examine the interim safety results of the trial.  During
  the third quarter, Marqibo received orphan drug designation from
  the European Medicines Evaluation Agency in adult ALL.  Hana
  previously received orphan drug and fast track designations for
  Marqibo for adult ALL from the U.S. Food and Drug Administration.
  The Company expects the IDMC interim analysis of the rALLy trial,
  as well as efficacy and safety updates from the trial during the
  first quarter of 2009.

* Menadione Topical Lotion for EGFRI-associated skin rash: Data
  presented at the European Society for Medical Oncology Conference
  demonstrated that topical menadione did not affect the anti-tumor
  effect of erlotinib (Tarceva(r)), an approved epidermal growth
  factor receptor inhibitor (EGFRI), in preclinical models.  Other
  preclinical data presented at the meeting showed menadione's
  ability to restore kinase activity in the presence of specific
  kinase inhibitors.  These data indicate that treatment with
  menadione may result in restoration of normal cell turnover rates
  and prevent skin toxicities that result from inhibition of protein
  kinases associated with tumor growth signaling pathways, such as
  the tyrosine kinases MEK, CDK and RAF.  Hana is currently
  evaluating menadione in a Phase 1 clinical trial for the treatment
  and/or prevention of EGFRI associated skin toxicities, and expects
  top-line data during the fourth quarter of 2008.  Currently, there
  are no FDA-approved products or therapies available to treat these
  skin toxicities.

* Alocrest(tm) for solid tumor cancers and lymphomas:  At the
  European Society for Medical Oncology Conference, Hana presented
  Phase 1 data for Alocrest, the Company's OPTISOME(tm) encapsulated
  formulation of vinorelbine tartrate.  Overall, this study achieved
  a disease control rate of 47 percent, including three of four
  elderly non-small cell lung cancer (NSCLC) subjects who achieved
  stable disease.  Of 27 subjects with refractory solid tumors and 3
  subjects with NHL evaluable for efficacy, one patient achieved a
  Partial Response (unconfirmed) and 13 patients achieved Stable
  Disease.  Alocrest was generally well-tolerated with reversible
  neutropenia as the most common dose limiting toxicity, and a
  maximum tolerated dose comparable to unencapsulated vinorelbine in
  heavily pre-treated patients.

Subsequent Events



* In November 2008, Hana initiated a Phase 1 trial with Brakiva(tm)
  (topotecan liposomes injection, OPTISOME(tm)) in advanced solid
  tumors in patients with small cell lung and ovarian cancers.  The
  primary objective is to evaluate the safety, tolerability, and to
  determine the maximum tolerated dose of Brakiva when administered
  to subjects with tumors that have relapsed, are refractory to
  standard treatment, or for whom there is no standard therapy
  available.  Secondarily, the study will assess the pharmacokinetic
  (PK) profile of Brakiva and examine the PK/pharmacodynamic
  relationship between measures of exposure and effect.  Data is
  expected at the end of 2009.

ADVERTISEMENT


Third Quarter 2008 Financial Results

The Company reported a net loss of $5.2 million, or $0.16 per share, for the three months ended September 30, 2008 compared to $5.1 million, or $0.16 per share, for the same period in 2007.

Research and development expense for the quarter ended September 30, 2008 was $4.3 million, compared to $5.7 million for three months ended September 30, 2007. The decrease in research and development costs was primarily due to decreased spending on earlier-stage pipeline programs partially offset by increased spending for clinical development of Marqibo and menadione.

General and administrative expenses totaled $1.0 million for the quarter ended September 30, 2008 compared with $0.5 million for the three months ended September 30, 2007. The increase was primarily due to an increase in employee related stock option expenses.

Cash used in operations was $5.5 million for the quarter ended September 30, 2008. As of September 30, 2008, the Company had cash and cash equivalents and available-for-sale securities of $3.8 million. In October 2007, the Company entered into a $30 million financing commitment with Deerfield Management, a leading healthcare investment fund, to finance ongoing working capital requirements of the development of the Company's pipeline of product candidates. On October 14, 2008, the Company borrowed $12.5 million under the agreement and on November 5, 2008 requested an additional $2.5 million.

``Our current cash balance along with the funds available through the Deerfield agreement will enable us to deliver valuable Phase 2 clinical data for Marqibo, and to further advance our lead pipeline programs,'' said John Iparraguirre, Vice President and Chief Financial Officer.

Conference Call

Hana Biosciences' management will host a conference call discussion today, November 13, 2008, at 5:00pm ET, 2:00pm PT.



Date:                        Thursday, November 13, 2008
Time:                        5:00pm ET, 2:00pm PT
Dial-in (U.S. and Canada):   (877) 407-8031
Dial-in (International):     (201) 689-8031
Webcast:                     http://www.hanabiosciences.com

A replay of this call will be available for one week by dialing (877) 660-6853 U.S./Canada and (201) 612-7415 for International participants. When prompted, enter Account Number #286 and Conference ID #301599. An archived version of the webcast will also be available via the company's website for 14 days following the call.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NasdaqCM:HNAB - News) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture. Further information on Hana Biosciences can be found at http://www.hanabiosciences.com.

The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include without limitation, statements regarding, the timing progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of Hana's product candidates. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its other product candidates will be successful, that Hana will be able to obtain regulatory approval of any of its product candidates, and that the results of clinical trials will support Hana's claims or beliefs concerning the effectiveness of its product candidates. Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.



                      HANA BIOSCIENCES, INC.
                     CONDENSED BALANCE SHEETS
                            (Unaudited)

                                         September 30,   December 31,
                                             2008            2007
                                         -------------  -------------

ASSETS
Current assets:
Cash and cash equivalents                $   3,743,357  $  20,795,398
Available-for-sale securities                   72,000         96,000
Prepaid expenses and other current
 assets                                        738,491        489,293
                                         -------------  -------------
 Total current assets                        4,553,848     21,380,691

Property and equipment, net                    445,436        432,529
Restricted cash                                125,000        125,000
Debt issuance costs                          1,395,296      1,423,380
                                         -------------  -------------
Total assets                             $   6,519,580  $  23,361,600
                                         =============  =============

LIABILITIES AND STOCKHOLDERS' EQUITY
 (DEFICIT)
Current liabilities:
Accounts payable                         $     270,311  $   1,682,739
Accrued other expenses                         187,330        496,239
Accrued personnel related expenses             637,600        763,050
Leased equipment: short-term                    48,085         13,919
Accrued clinical development costs           2,092,441      1,156,011
                                         -------------  -------------
 Total current liabilities                   3,235,767      4,111,958
                                         -------------  -------------

Notes payable                                2,189,716      2,025,624
Warrant liabilities                          2,032,523      4,232,355
Leased equipment: long-term                     58,680         33,861
                                         -------------  -------------
Total long term liabilities                  4,280,919      6,291,840
                                         -------------  -------------
Total liabilities                            7,516,686     10,403,798
Commitments and contingencies

Stockholders' equity (deficit):
Common stock; $0.001 par value:
 100,000,000 shares authorized,
 32,386,130 and 32,169,553 shares issued
 and outstanding at September 30, 2008
 and December 31, 2007, respectively            32,386         32,170
Additional paid-in capital                 103,903,612    101,843,390
Accumulated other comprehensive loss           (20,000)      (104,000)
Accumulated deficit                       (104,913,104)   (88,813,758)
                                         -------------  -------------
Total stockholders' equity (deficit)          (997,106)    12,957,802
                                         -------------  -------------
Total liabilities and stockholders'
 equity (deficit)                        $   6,519,580  $  23,361,600
                                         =============  =============


                      HANA BIOSCIENCES, INC.
  CONDENSED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS
                            (Unaudited)

                    Three Months Ended         Nine Months Ended
                       September 30,             September 30,
                 ------------------------  --------------------------
                    2008          2007         2008          2007
                 -----------  -----------  ------------  ------------
License revenue  $        --  $ 1,150,000  $         --  $  1,150,000

Operating
 expenses:
General and
 administrative      973,414      481,155     4,623,889     6,553,502
Research and
 development       4,347,265    5,730,859    13,031,060    17,442,556
                 -----------  -----------  ------------  ------------
Total operating
 expenses          5,320,679    6,212,014    17,654,949    23,996,058

Loss from
 operations       (5,320,679)  (5,062,014)  (17,654,949)  (22,846,058)
                 -----------  -----------  ------------  ------------

Other income
 (expense):
Interest income       39,997      265,307       271,361       972,932
Interest expense    (254,569)      (1,138)     (756,211)       (3,807)
Other expense,
 net                 (8,516)      (42,418)      (51,380)      (61,057)
Gain or loss on
 derivative          382,152           --     2,199,833            --
Realized loss on
 marketable
 securities               --     (260,000)     (108,000)     (436,000)
                 -----------  -----------  ------------  ------------
Total other
 income (expense)    159,064      (38,249)    1,555,603       472,068

Net loss         $(5,161,615) $(5,100,263) $(16,099,346) $(22,373,990)
                 ===========  ===========  ============  ============
Net loss per
 share, basic
 and diluted     $     (0.16) $     (0.16) $      (0.50) $      (0.75)
                 ===========  ===========  ============  ============

Weighted average
 shares used in
 computing net
 loss per share,
 basic and
 diluted          32,385,366   31,197,295    32,265,010    29,958,487
                 ===========  ===========  ============  ============
Comprehensive
 loss:
Net loss         $(5,161,615) $(5,100,263) $(16,099,346) $(22,373,990)
Unrealized
 holdings gains
 (losses) arising
 during the
 period              (20,000)          --      (128,000)     (456,000)
Less:
 reclassification
 adjustment for
 losses included
 in net loss              --           --       108,000       436,000
                 -----------  -----------  ------------  ------------

Comprehensive
 loss            $(5,181,615) $(5,100,263) $(16,119,346) $(22,393,990)
                 ===========  ===========  ============  ============



Contact:
         Hana Biosciences
         Investor & Media Contacts:
         Investor Relations Team
         (650) 588-6641
         investor.relations@hanabiosciences.com

         Invigorate Communications
         Gregory Gin
         (908) 376-7737
         ggin@invigoratepr.com


--------------------------------------------------
Source: Hana Biosciences, Inc.

SOUTH SAN FRANCISCO, Kalifornien, November 13, 2008 (GLOBE NEWSWIRE) - Hana Biosciences (NasdaqCM: HNAB - News), ein biopharmazeutisches Unternehmen, das sich auf die Stärkung der Stiftung der Krebsbehandlung, gab heute bekannt, seine finanziellen und operativen Ergebnisse wesentlichen Kennzahlen für das dritten Quartal zum 30. September 2008.
`` Im Verlauf des dritten Quartals 2008 haben wir zur Erzielung einer signifikanten Fortschritte bei der Weiterentwicklung unserer Pipeline von Dosis-Wirkungs-Intensivierung und Verbesserung der Compliance-Onkologie Produkt Kandidaten, Adresse beträchtlichen kommerziellen Möglichkeiten, wie durch die positiven Ergebnisse aus unseren beiden wichtigsten Pipeline-Kandidaten, Marqibo und Menadion,''sagte Steven R. Deitcher, MD, President und Chief Executive Officer von Hana Biosciences. `` Wir erwarten, auf diese Fortschritte in den kommenden Monaten, da wir weiterhin den Schwerpunkt unserer Investitionen, und wir weiterhin auf dem richtigen Weg zur Erreichung mehrerer kurzfristigen Meilensteine, in diesen Initiativen höchste Priorität.''

Drittes Quartal 2008 wesentliche erfolge



 * Marqibo (r) für erwachsene akute lymphatische Leukämie (ALL): Hana's
   -Registrierung, die Phase-2-RALLYE zentrale klinische Studie der
   Marqibo (Vincristin Sulfat Injektion, OPTISOME (tm)) erfolgreich
   erreicht, die im Voraus festgelegten Protokoll Anforderung von mindestens 3
   vollständige Antworten oder vollständige Antworten ohne volle Thrombozytenzahl
   Erholung unter den ersten 29 auswertbaren Patienten, um volle
   Immatrikulation von 56 Patienten mit ALL in der zweiten Rückfall. Nach Hana
   vervollständigt die Immatrikulation der ersten 29 Patienten, die Daten werden
   dem Independent Data Monitoring Committee (IDMC),
   , die die Zwischen-Sicherheit Ergebnisse der Studie. Während
   das dritte Quartal, Marqibo erhalten Orphan-Drug aus
   der Europäischen Arzneimittel-Agentur für die Beurteilung bei erwachsenen ALL. Hana
   zuvor Orphan-Drug-und Fast-Track-Bezeichnungen für
   Marqibo für erwachsene ALL von der US Food and Drug Administration.
   Die Gesellschaft erwartet, dass die IDMC Zwischenanalyse der Rally-Prozess,
   sowie die Wirksamkeit und Sicherheit von Updates aus dem Prozess während der
   ersten Quartal 2009.

 * Menadion Aktuelle Lotion für EGFRI-assoziierten Hautausschlag: Die Daten
   präsentiert auf der Tagung des Europäischen Gesellschaft für Medizinische Onkologie-Konferenz
   gezeigt, dass aktuelle Menadion hatte keinen Einfluss auf die Anti-Tumor
   Wirkung von Erlotinib (Tarceva (R)), einem zugelassenen epidermalen Wachstumsfaktor
   Faktor-Rezeptor-Inhibitor (EGFRI), in präklinischen Modellen. Andere
   präklinischen Daten, präsentiert auf der Tagung zeigte Menadion's
   Potenzial zur Wiederherstellung der Kinase-Aktivität in Anwesenheit von spezifischen
   Kinase-Hemmer. Diese Daten deuten darauf hin, dass die Behandlung mit
   Menadion kann dazu führen, dass die Wiederherstellung der normalen Zelle Umsatz Sätze
   und Vermeidung von Hautkontakt Toxizitäten, die durch eine Hemmung der Protein -
   Kinasen im Zusammenhang mit der Tumor-Wachstum Signalwege, wie z. B.
   die Tyrosin-Kinasen MEK, CDK und RAF. Hana ist derzeit
   Bewertung Menadion in einer klinischen Phase-1-Studie für die Behandlung
   und / oder Vorbeugung von Haut EGFRI verbundenen Toxizitäten, und erwartet,
   Top-line-Daten im vierten Quartal 2008. Derzeit gibt
   es keine FDA-zugelassenen Produkten oder Therapien zur Behandlung dieser
   Haut Toxizitäten.

 * Alocrest (tm) für feste Tumor Krebs und Lymphome: Auf dem
   Europäischen Gesellschaft für Medizinische Onkologie-Konferenz, Hana präsentiert
   Phase-1-Daten für Alocrest, der Gesellschaft OPTISOME (tm) gekapselt
   Formulierung von Vinorelbin Tartrat. Insgesamt ist dieser Studie erreicht
   Seuchenbekämpfung ein Satz von 47 Prozent, darunter drei der vier
   ältere Menschen nicht-kleinzelligem Lungenkarzinom (NSCLC) Themen, die erreicht
   stabile Krankheit. Von 27 Patienten mit refraktären soliden Tumoren und 3
   Patienten mit NHL auswertbaren für die Wirksamkeit, ein Patient erreichte eine
   Partial Response (unbestätigten) und 13 Patienten erreicht Stabile
   Krankheit. Alocrest wurde im Allgemeinen gut verträglich mit reversibel
   Neutropenie als die häufigste Dosis Begrenzung der Toxizität, und ein
   maximal verträgliche Dosis vergleichbar mit unverkapseltem Vinorelbin in
   stark vorbehandelten Patienten.

Nachfolgende Veranstaltungen



 * Im November 2008, Hana eine Phase-1-Studie mit Brakiva (tm)
   (Topotecan Liposomen Injektion, OPTISOME (tm)) in fortgeschrittenen soliden
   Tumoren bei Patienten mit kleinen Lungenkarzinom und Eierstockkrebs Krebserkrankungen. Der
   Vorrangiges Ziel ist die Evaluierung der Sicherheit, Verträglichkeit und
   Bestimmung der maximal verträglichen Dosis von Brakiva, wenn es
   an Patienten mit Tumoren, die rezidivierendem, sind die refraktär
   Standard-Behandlung, oder, für die es keine Standard-Therapie
   verfügbar. In zweiter Linie, die Studie wird die pharmakokinetischen
   (PK) Profil der Brakiva und prüfen die PK / pharmakodynamischen
   Beziehung zwischen den Maßnahmen der Exposition und Wirkung. Die Daten werden
   voraussichtlich Ende 2009.

WERBUNG
 
 
Drittes Quartal 2008 Financial Results

Das Unternehmen berichtete einen Nettoverlust von 5,2 Millionen Dollar oder 0,16 Dollar je Aktie, für die abgeschlossenen drei Monate per 30. September 2008 im Vergleich zu 5,1 Millionen Dollar oder 0,16 Dollar je Aktie, für den gleichen Zeitraum in 2007.

Forschung und Entwicklung Aufwendungen für das Quartal zum 30. September 2008 war 4,3 Millionen Dollar, verglichen mit 5,7 Millionen Dollar für die drei Monate per 30. September 2007. Der Rückgang der Forschungs-und Entwicklungskosten in erster Linie auf verringerte Ausgaben für die früheren Phase-Pipeline-Programmen teilweise ausgeglichen durch höhere Ausgaben für die klinische Entwicklung von Marqibo und Menadion.

Allgemeine und Verwaltungskosten insgesamt $ 1,0 Millionen für das Quartal zum 30. September 2008, verglichen mit 0,5 Millionen Dollar für die abgeschlossenen drei Monate per 30. September 2007. Der Anstieg war in erster Linie auf eine Erhöhung der Mitarbeiter im Zusammenhang Stock-Options-Aufwendungen.

Cashflow aus Geschäftstätigkeit war 5,5 Millionen Dollar für das Quartal zum 30. September 2008. Ab 30. September 2008 hatte das Unternehmen liquide Mittel und zur Veräußerung verfügbare Wertpapiere von 3,8 Mio. Dollar. Im Oktober 2007 hat die Gesellschaft in eine $ 30 Millionen Finanzierung Engagement mit Deerfield Management, einer der führenden Healthcare Investment Fonds, die Finanzierung von laufenden Working Capital Anforderungen der Entwicklung der Gesellschaft Pipeline von Produktkandidaten. Am 14. Oktober 2008 hat die Gesellschaft Fremdmittel 12,5 Mio. Dollar im Rahmen der Vereinbarung und am 5. November 2008 beantragte eine zusätzliche 2,5 Millionen Dollar.

`` Unsere aktuellen Cash-Balance zusammen mit den zur Verfügung stehenden Mittel durch die Deerfield Abkommen ermöglicht uns, liefern wertvolle Phase 2 der klinischen Daten für Marqibo, und weiter zu führen unsere Pipeline-Programmen,''sagte John IPARRAGUIRRE, Vice President und Chief Financial Officer.

Conference Call

Hana Biosciences "Management wird eine Telefonkonferenz Diskussion heute, 13. November 2008, 5.00 Uhr am ET, 2:00 pm PT.



 Datum: Donnerstag, 13. November, 2008
 Zeit: 5:00 Uhr ET, 2:00 pm PT
 Dial-in (US und Kanada): (877) 407-8031
 Dial-In (International): (201) 689-8031
 Webcast: http://www.hanabiosciences.com

Eine Aufzeichnung dieser Aufforderung werden für eine Woche durch die Einwahl (877) 660-6853 USA / Kanada und (201) 612-7415 für internationale Teilnehmer. Wenn Sie gefragt werden, geben Sie Account Number # 286 und die Konferenz ID # 301599. Eine archivierte Version des Webcast wird ebenfalls über die Website des Unternehmens für 14 Tage nach dem Aufruf.

Über Hana Biosciences, Inc.

Hana Biosciences, Inc. (NasdaqCM: HNAB - News) ist ein South San Francisco, CA-basierte biopharmazeutisches Unternehmen, das sich auf den Erwerb, die Entwicklung und Vermarktung innovativer Produkte zur Stärkung der Stiftung der Krebsbehandlung. Das Unternehmen hat sich verpflichtet, Schaffung von Mehrwert durch den Aufbau einer Best-in-Class-Team, die Beschleunigung der Entwicklung von Produkt-Kandidaten führen, baut seine Pipeline durch die Allianz ein Partner der Wahl, und die Pflege einer einzigartigen Unternehmenskultur. Weitere Informationen zu Hana Biosciences finden Sie unter http://www.hanabiosciences.com.

Die Hana Biosciences, Inc. Logo ist erhältlich unter http://www.globenewswire.com/newsroom/prs/?pkgid=3290

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act "von 1995. Diese Aussagen sind zwar häufig, aber nicht immer, durch die Verwendung von Wörtern oder Sätzen wie `` erwartet,''`` erwartet,''`` Pläne,''`` ist der Auffassung,''`` beabsichtigt,''und ähnliche Wörter oder Ausdrücke. Diese zukunftsgerichteten Aussagen gehören ohne Beschränkung, Aussagen über die zeitlichen Fortschritt und erwartete Ergebnisse der klinischen Entwicklung, regulatorische Prozesse, potenziellen klinischen Studie Initiationen, potenzielle IND und NDA Anmeldungen und Kommerzialisierung Bemühungen der Hana-Produkt Kandidaten. Solche Aussagen beinhalten Risiken und Unsicherheiten, die dazu führen, dass Hana die tatsächlichen Ergebnisse wesentlich von den erwarteten Ergebnissen und Erwartungen in diese zukunftsgerichteten Aussagen. Diese Aussagen beruhen auf derzeitigen Erwartungen, Prognosen und Annahmen, unterliegen Risiken und Unsicherheiten, die dazu führen, dass tatsächliche Ergebnisse erheblich von diesen Aussagen. Unter anderem kann es keinerlei Zusicherung, dass der Hana die Entwicklung Anstrengungen in Bezug auf seine anderen Produktkandidaten von Erfolg gekrönt sein wird, dass Hana werden können, um behördlichen Genehmigung für eines seiner Produkt-Kandidaten, und dass die Ergebnisse von klinischen Prüfungen wird Hana Forderungen oder Überzeugungen über die Wirksamkeit ihrer Produktkandidaten. Zusätzliche Risiken, die sich auf die in diesen zukunftsgerichteten Aussagen gehören Hana's brauchen zusätzliches Kapital zur Finanzierung ihrer Produktentwicklung Programmen bis zur Fertigstellung, Hana die Abhängigkeit von Drittanbieter-Forscher für die Entwicklung seiner Produktkandidaten, und ihren Mangel an Erfahrung in der Entwicklung und Kommerzialisierung von pharmazeutischen Produkten . Weitere Risiken sind in den Unternehmen des Jahresberichts auf Formular 10-K für das Geschäftsjahr zum 31. Dezember 2007 bei der Securities and Exchange Commission. Hana übernimmt keine Verpflichtung zur Aktualisierung dieser Aussagen, es sei denn, gesetzlich vorgeschrieben.



                       Hana Biosciences, Inc.
                      Verkürzte Bilanz
                             (Ungeprüft)

                                          30. September, 31. Dezember,
                                              2008 2007
                                          ------------- -------------

 AKTIVA
 Kurzfristige Vermögenswerte:
 Zahlungsmittel und Zahlungsmitteläquivalente $ 3743357 $ 20795398
 Zur Veräußerung verfügbare Wertpapiere 72000 96000
 Rechnungsabgrenzungsposten und sonstige kurzfristige
  Vermögenswerte 738491 489293
                                          ------------- -------------
  Total Umlaufvermögen 4553848 21380691

 Sachanlagen, netto 445436 432529
 Sicherheit hinterlegte liquide Mittel 125000 125000
 Debt Issuance Kosten 1395296 1423380
                                          ------------- -------------
 Summe der Aktiva $ 6519580 $ 23361600
                                          ============= =============

 Verbindlichkeiten und Eigenkapital
  (VERLUST)
 Kurzfristige Verbindlichkeiten:
 Verbindlichkeiten aus Lieferungen und Leistungen $ 270311 $ 1682739
 Rückstellungen für sonstige Aufwendungen 187330 496239
 Rückstellungen für Personalkosten im Zusammenhang Aufwendungen 637600 763050
 Anlagen Leased: kurzfristige 48085 13919
 Rückstellungen für die Kosten der klinischen Entwicklung 2092441 1156011
                                          ------------- -------------
  Laufende Verbindlichkeiten insgesamt 3235767 4111958
                                          ------------- -------------

 Schuldscheindarlehen 2189716 2025624
 Warrant Verbindlichkeiten 2032523 4232355
 Anlagen Leased: langfristige 58680 33861
                                          ------------- -------------
 Total langfristige Verbindlichkeiten 4280919 6291840
                                          ------------- -------------
 Passiva insgesamt 7516686 10403798
 Haftungsverhältnisse und sonstige finanzielle Verpflichtungen

 Eigenkapital (Defizit):
 Stammaktien, $ 0,001 Nennwert:
  100.000.000 genehmigten Aktien
  32.386.130 und 32.169.553 Aktien
  und im Umlauf am 30. September 2008
  und 31. Dezember, 2007 bzw. 32386 32170
 Kapitalrücklage 103.903.612 101.843.390
 Kumuliertes sonstiges Gesamtergebnis: (20000) (104000)
 Bilanzverlust (104.913.104) (88813758)
                                          ------------- -------------
 Summe Eigenkapital (Defizit) (997106) 12957802
                                          ------------- -------------
 Passiva, gesamt "
  Eigenkapital (Defizit) $ 6519580 $ 23361600
                                          ============= =============


                       Hana Biosciences, Inc.
   Verkürzte Gewinn-und Verlustrechnungen und andere umfassende Verlust
                             (Ungeprüft)

                     Drei Monate zum Neun Monate beendet
                        30. September, 30. September,
                  ------------------------ --------------------------
                     2008 2007 2008 2007
                  ----------- ----------- ------------ ------------
 Lizenz-Einnahmen $ - $ 1150000 $ - $ 1150000

 Betriebsergebnis
  Kosten:
 Allgemeine und
  Verwaltungsvorschriften 973414 481155 4623889 6553502
 Forschung und
  Entwicklung 4347265 5730859 13031060 17442556
                  ----------- ----------- ------------ ------------
 Der Geschäftsaufwand
  Ausgaben 5320679 6212014 17654949 23996058

 Verlust aus
  Operationen (5320679) (5062014) (17654949) (22846058)
                  ----------- ----------- ------------ ------------

 Sonstige Erträge
  (Aufwand):
 Zinserträge 39.997 265.307 271.361 972.932
 Zinsaufwand (254.569) (1138) (756.211) (3807)
 Übriger Aufwand,
  net (8516) (42.418) (51.380) (61.057)
 Gewinn oder Verlust aus
  Derivat von 382152 bis 2199833 --
 Realisierte Verluste auf
  marktfähige
  Wertpapiere - (260.000) (108.000) (436.000)
                  ----------- ----------- ------------ ------------
 Anzahl der anderen
  Erträge (Aufwendungen) 159064 (38249) 1555603 472068

 Net loss $ (5161615) $ (5100263) $ (16099346) $ (22373990)
                  =========== =========== ============ ============
 Ergebnis je
  Aktie, unverwässert
  und verwässert $ (0,16) $ (0,16) $ (0.50) $ (0.75)
                  =========== =========== ============ ============

 Gewichteter Durchschnitt der
  Aktien, die in
  Netto-Computing
  Das Ergebnis je Aktie,
  Grund-und
  verdünnten 32385366 31197295 32265010 29958487
                  =========== =========== ============ ============
 Umfassende
  Verlust:
 Net loss $ (5161615) $ (5100263) $ (16099346) $ (22373990)
 Nicht realisierte
  Betriebe Gewinne
  (Verluste) aus
  während der
  Zeitraum (20000) - (128.000) (456.000)
 Abzüglich:
  Neueinstufung
  Berichtigung für
  Verluste enthalten
  der Netto-Verlust - - 108.000 436.000
                  ----------- ----------- ------------ ------------

 Umfassende
  Verlust $ (5181615) $ (5100263) $ (16119346) $ (22393990)
                  =========== =========== ============ ============



Kontakt:
          Hana Biosciences
          Investor & Media Contacts:
          Investor Relations Team
          (650) 588-6641
          investor.relations @ hanabiosciences.com

          Beleben Communications
          Gregory Gin
          (908) 376-7737
          ggin@invigoratepr.com


-------------------------------------------------- ------------------------------
Quelle: Hana Biosciences, Inc.

Da bin ich ja mal gespannt.


Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting
Monday December 1, 7:30 am ET


SOUTH SAN FRANCISCO, Calif., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (NasdaqCM:HNAB - News), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.
The following posters will be presented in Hall A of the Moscone Center at the ASH annual meeting. Text of these abstracts can be viewed on the ASH website at http://www.hematology.org.


* In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes
  Injection (VSLI, Marqibo) in Multiple Myeloma   (abstract #2760;
  Sunday, Dec. 7, 6:00 PM)

* Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes
  Injection (VSLI, Marqibo), a Nanoparticle Vincristine Formulation,
  in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic
  Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL)  (abstract #2928;
  Monday, Dec. 8, 5:30 PM)

* Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes
  Injection (VSLI, Marqibo) Plus Dexamethasone in Adults with Relapsed
  or Refractory Acute Lymphoblastic Leukemia (ALL) (abstract #2930;
  Monday, Dec. 8, 5:30 PM)

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (NasdaqCM:HNAB - News) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture. Further information on Hana Biosciences can be found at http://www.hanabiosciences.com.

The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290



Contact:
         Hana Biosciences
         Investor & Media Contacts:
         Investor Relations Team
         (650) 588-6641
         investor.relations@hanabiosciences.com

         Invigorate Communications
         Gregory Gin
         (908) 376-7737
         ggin@invigoratepr.com


--------------------------------------------------
Source: Hana Biosciences, Inc.

Und da kommen sie wieder aus ihren Löchern gekrochen...  

und versprechen 1000de von Prozenten....

irgendwoher kenne ich das doch!?    Hana Biosciences...Analysen von kleinen deutschen Zockern...    

Man staune und wundere sich wie kleine deutsche Zocker - Analysen über amerikanische Bio Titel aus der Tasche zaubern...als seien sie vor Ort gewesen und dem Treiben dieser unbedeutenden   Bio-Wunder zugeschaut haben.     Eher ist es wohl so, dass man sich auf Micro-Penny Stock Niveau  mit "Zertifikaten" eingedeckt hat ...und nun die vermeindlich billigen Zettel mit vollmundigen Gewinnversprechen den deutschen Lemmingen   aufs Auge drücken will....Der Trick ist uralt!    

Es hat schon seinen Grund warum solche Titel abgestürzt sind!   Die Biowunder versprechen viel und machen n u r Verluste. In USA notieren 1000e solcher Biotüten in verschiedenen Indizies.

Paradebeispiel Biophan 0,001 wo stand der Titel mal!?

Heisse Luft..viele krabbeln am Existenzminimum und bei den Meisten wird irgendwann mit Sicherheit das Licht ausgehen. Weil der Energieversorger gesperrt hat.

Sie forschen sich zu Tode...und forschen und forschen, bis ein Wunder geschieht?    Nur wenigen gelang es sich über 1 Dollar zu halten. Im Gegenteil, die Richtung ist vorbestimmt 0,10 $ und darunter. Bis ein letztes Aufbäumen - die Gier nach schnellem Geld einige Lemminge zum Kauf verführt.    

Man sollte genau überlegen in was man sein gutes Geld tauscht, besser in Premiumwerte investieren Eli Lilly, Fizer, Amgen usw. und nicht in irgendwelche Zockerbuden...die Geld nur verbrennen.

 

 

Drittes Quartal 2008 Financial Results

 

Das Unternehmen berichtete einen Nettoverlust von:

5,2 Millionen Dollar oder 0,16 Dollar je Aktie. 

 

 

 

 

 

 

und mit 300 Stückchen wieder hochgezogen ...ein jämmerliches Bild...

 

USA 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

am Freitag.
Auffällig ist das hohe Volumen. Hier wurden mehr Aktien gehandelt als an den restlichen Wochentagen  zusammen.
Sind etwa schon im Vorfeld Ergebnisse vorder Veröffentlichung durchgesickert? Oder sind es positive Erwartungen auf gute News?
Mal schauen, morgen wissen wir mehr.

Hana Biosciences Completes Phase 1 Clinical Trial of Menadione, Its Novel First-in-class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors
Date: 12/8/2008 7:30:16 AM

Menadione Topical Lotion Exhibits Excellent Safety Profile and Favorable Pharmacokinetics With No Appreciable Systemic Absorption
SOUTH SAN FRANCISCO, Calif., Dec 8, 2008 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the successful completion of its Phase 1 clinical study in healthy volunteers of menadione topical lotion, its novel first-in-class compound in development for the prevention and/or treatment of the acneiform skin rash complication due to anti-cancer therapy with epidermal growth factor receptor (EGFR) inhibitors.
Study results showed that menadione was well tolerated at all doses tested. The open-label, modified dose-escalation study assessed the bioavailability, safety and tolerability of three concentrations (0.05%, 0.1% and 0.2%) of menadione and placebo administered to 12 healthy subjects with intact skin. Menadione or placebo was applied on the face, neck, upper chest and upper arms for 3.5 days every 7 days over a 28 day period. The study included skin biopsy specimens for analysis, patient tolerability questionnaires, and full pharmacokinetic sampling on all of the subjects at the various lotion strengths.

"We are encouraged by these study results that show study subjects experienced no appreciable systemic absorption of menadione at any concentration, which supports previously reported preclinical data that showed menadione does not interfere with the anti-cancer activity of EGFR inhibitors," said Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. "We are very excited about the potential for this promising novel agent and are convinced that successful prevention and treatment of this skin toxicity is needed to maintain compliance of the anti-cancer therapy."

Acneiform rash is a common, painful, and treatment-limiting skin toxicity side effect of all EGFR inhibitors (e.g. Tarceva(r), Iressa(r), Erbitux(r), Vectibix(r)) with incidence rates as high as 90%. The skin rash can lead to reduced compliance and cause dose reductions, delays or discontinuation of EGFR inhibitor therapy in a significant portion of affected patients. Currently, there are no products or therapies FDA-approved to treat these skin toxicities.

Results from past preclinical studies demonstrated that menadione does not affect the anti-tumor effect of erlotinib (Tarceva(r)), an approved EGFR inhibitor. Other preclinical data showed menadione's ability to restore kinase activity in the presence of specific kinase inhibitors. These data indicate that treatment with menadione may result in restoration of normal cell turnover rates and prevent skin toxicities that result from inhibition of protein kinases associated with tumor growth signaling pathways, such as the tyrosine kinases EGFR, MEK, CDK and RAF.

In the completed Phase 1 study, adverse events considered at least possibly related to menadione that occurred most frequently included skin erythema and burning sensation that increased in frequency with concentration levels.

A Phase 1 study in patients receiving EGFR inhibitors for anti-cancer therapy in both rash emergent and rash pre-emergent settings is ongoing, and the Company expects to initiate a randomized Phase 2 trial during the first half of 2009.

About Menadione Topical Lotion

Menadione, a small organic molecule, is a novel, potential first-in-class compound that is designed to prevent or treat skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitor anti-cancer therapy. EGFR inhibitors, or EGFRIs, are currently used to treat over 100,000 patients per year with a variety of cancers including non-small cell lung, pancreatic, colorectal, and head & neck cancer. Loss of EGFR signaling has been hypothesized as a mechanism of skin toxicity in patients receiving EGFRIs. The rash occurs primarily on the face, neck, and upper torso.

Menadione has been shown to activate the EGFR signaling pathway by blocking phosphatase activity in preclinical studies. In vitro studies suggest that topically-applied menadione may restore EGFR signaling at the dermal/epidermal junction, which could prove beneficial to patients who receive EGFRI cancer therapy. Hana Biosciences in-licensed menadione from the Albert Einstein College of Medicine in New York in October 2006. A Phase 1 clinical trial is ongoing in the U.S. and Canada.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture. Further information on Hana Biosciences can be found at www.hanabiosciences.com.

der Puscher-Trick hat nicht funktioniert.
Heute weiterer Absturz um -26%...

Auf so was fällt niemand mehr rein.
HANA (HAHA) Bioscience war auch mal DIE Biotech-Perle vom Aktionär.
Wobei die Betonung auf UNENTDECKT lag.

Aber damals bewegte man sich noch bei 6 Euros.
Heute sinds noch 15 cents  

http://news.prnewswire.com/.../story/03-03-2009/0004981720&EDATE=  

Schönes Plus in den USA. Kommt hier bald was Großes?  

Hana Biosciences: Primed for a Major Comeback

 

 

It looks like the perfect storm is brewing for Hana Biosciences (HNAB).

In December, the stock took a major hit for no reason other than possibly some impatient investors selling off. Going into what should be a very positive year with a new drug application (NDA) filing for their drug Marquibo after successful trial results, this stock is primed for some major movement in the near future; first a reset to the 60-80 cent level, then a move higher as the NDA is filed.

The December publication of results from the rALLy trial in acute lymphoblastic leukemia (ALL) in second relapse shows that the drug was highly efficient as a single-agent in a very sick patient population who have few other options. There are no safety concerns beyond what is expected for this type of drug. The FDA has a history of approving ALL treatments based on phase II single-arm clinical trials, and Hana intents to use the results of the rALLy trial in their NDA filing later on this year. Accelerated approvals have already been given for the drugs Clolar and Arranon for other ALL indications based on single-arm phase II studies.

The company released a corporate presentation last week. Click the link for a pdf version of the presentation.

Marquibo is a new form of a trusted cancer drug, vincristine sulfate, in a liposome delivery vehicle. This delivery mechanism enables higher doses of the drug to be used while reducing the side effects. In the long run, Hana hopes to replace the use of generic vincristine with Marquibo in the R-CHOP leukemia treatment regimen across the board, a predicted market potential of $2.5 billion annually. The 2nd relapsed adult ALL market alone is $100 million with 65% penetration, see the company's slide number 23. The choice of second relapse adult ALL is a good strategy to enter the market. The drug was previously scrutinized by the FDA's oncology drug advisory committee in December of 2004 for another indication,aggressive non-Hodgkin's lymphoma previously treated with at least two combination chemotherapy regimens. At the time, the drug was owned by Inex Pharmacuticals. The NDA in 2004 was also based on phase II clinical trials, and although it showed equivalence, it did not show superiority to other current treatments - Inex had chosen the wrong pathway for approval. It is important to note that the committee members were otherwise very positive to the drug and no safety questions were raised. This time around, the rALLy trial has shown a major advantage to the patients over historical data, and the primary investigator for the rALLy trial is none other than Dr. Susan O'Brien, a leading expert on leukemia treatment with strong clinical trial experience.
For those who enjoy reading stock charts, the consensus is that HNAB is currently due for a major reset, unrelated to other upcoming events. This annotated chart was prepared by user EpicStocks on InvestorsHub, and tells the tale very nicely. It is rare to come across a biopharma stock with upcoming drug submissions and a perfect chart situation, this is the first in some time. The company has cash to last until the NDA submission, and more on tap through Deerfield Management, who has a seat on the board of directors. Some minor dilution is expected as we move forward, but this is still a company with a low float, currently at only 92 million shares outstanding with a float of 81 million shares.

Disclosure: Long HNAB

http://seekingalpha.com/article/...-for-a-major-comeback?source=yahoo

 

 

DALLAS, Jan. 25, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Hana Biosciences Incorporated (OTCBB:HNAB - News). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. 

 

The full report is available at: http://www.beaconequity.com/i/HNAB

 

 

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

 

 

Hana Biosciences Incorporated (HNAB) engages in the biotechnological development and commercialization of cancer therapies to enhance efficacy to current standard-of-care protocols for the treatment of various cancers. The Company presently has four drug candidates under development, including Marqibi ®, Menadione Topical Lotion, Brakiva (TM) and Alocrest (TM).

 

In the report, the analyst notes:

 

"As of September 30, the Company's drug candidate Marqibo is in phase II for the treatment of metastatic uveal melanoma. The Company achieved its target enrollment in 2009, with plans for a confirmatory trial of the drug in 2011 and intentions to file for a New Drug Applications (NDA) with the Food and Drug Administration (FDA) in 2010. Further progression toward commercialization of Marqibo is dependent upon pending results of phase II studies. 

 

"The Company expects to report an additional $5.0 million of expenses related to Marqibo in its coming fourth-quarter earnings report. In its latest 10-Q filing in October, the Company said it needs an additional $8.0 million for an accelerated approval of Marqibo and $45.0 million for full FDA approval. Marqibo is expected to undergo three to four more years of development and FDA approval time before the Company can embark with commercialization of the product."

 

To read the entire report visit: http://www.beaconequity.com/i/HNAB

 

 

See what investors are saying about these stocks at penny stock forum. 

 

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

 

 

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

http://finance.yahoo.com/news/...-Hana-pz-604084091.html?x=0&.v=1

 

"Kommt bei Hana ein Rebound?" war die Frage? Antwort: JA. Begründung? Marqibo funktioniert. Das Krebs-Chemo-Sulfat Vincristine in der "Optisome" -modifizierten Darreichungsform heilt eine signifikante Anzahl von Probanden - noch dazu rückfällige oder auf eine herkömmliche Vincristine-Therapie nicht ansprechende ALL-Todeskandidaten. Dieses, soweit ich es prüfen kann, seriöses Zwischenergebnis der multinationalen rALLy-Studie ist ein Hammer und wird in sehr absehbarer Zeit ( Fast Track bereits erteilt ) zu einer Markteinführung von Marqibo als alternative Medikation bei lymphoblastischer Leukämie führen. Und das wäre der Startschuß für eine neue Medikamentengattung, denn der Lipidkügelchen-Trick ist übertragbar - und patentrechtlich geschützt! Hana ist an der Börse nahezu "wertlos", klassisches gemitteltes Kurs / Umsatz-Verhältnis von Drugmakern liegt so bei 2,5. Kursphantasie? 20 Dollar in 2-3 Jahren. Read my lips. Ich lasse mich an diesem Statement messen.  

 

Skymark Research Initiates Independent Research Coverage on Hana Biosciences

 

CALGARY, Alberta, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Hana Biosciences (OTCBB:HNAB - News).   Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

 

 

About SMR:

 

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php

 

 

The Skymark Research logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6683

 

 

About  Hana Biosciences (OTCBB:HNAB - News)

 

Hana Biosciences (OTCBB:HNAB - News) is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company's lead product candidate, Marqibo^(R), potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities, some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.

 

SMR Disclosure:

 

http://finance.yahoo.com/news/...ates-pz-2408557104.html?x=0&.v=1

 

Das Hana Biosciences kurz vor dem durchbruch ist ;-)

 

 

 

Neuer Run auf Biotech: Drei heiße Aktien vor der Entscheidung  

 

Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »